Clofert MAX

Quick links to important sections

Clofert MAX

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clofert MAX

Clofert MAX is a prescription-only pharmaceutical agent, often supplied in an oral tablet form, specifically designed as a dual-therapy approach to enhance reproductive capacity. Its unique formulation combines a synthetic hormonal agent with an endogenous micronutrient to address both regulatory cycles and cellular quality.


Property Description
Active Ingredients Clomifene, Coenzyme Q10 (Ubidecarenone)
Form Tablet / Kit
Pharmacological Class Selective Estrogen Receptor Modulator (SERM) and Antioxidant/Nutraceutical combination
Common Use Supporting conception processes by promoting ovulation and improving cellular health
Origin Synthetic (Clomifene) and Endogenous/Vitamin-like (Coenzyme Q10)

What Type of Medicine is Clofert MAX? (Identity and Classification)

Clofert MAX is characterized by its combination of Clomifene, a Synthetic agent belonging to the Selective Estrogen Receptor Modulator (SERM) class, and Coenzyme Q10 (Ubidecarenone), a vitamin-like, Endogenous antioxidant. Clomifene is recognized as a nonsteroidal ovulatory stimulant with both estrogenic and anti-estrogenic activities, competing with estrogen for receptor binding. This dual composition is a differentiating factor, moving beyond the monotherapy approach of Clomifene alone to integrate metabolic support.

Composition and General Purpose of the Combined Therapy

The formulation’s efficacy is driven by the synergistic action of its two main ingredients. Clomifene citrate functions primarily to modulate the hormonal feedback system, promoting the necessary stimulus for the release of an egg. Simultaneously, Coenzyme Q10 is included to provide robust cellular energy and antioxidant protection to reproductive tissues. Coenzyme Q10 is essential for ATP synthesis and protection from oxidative stress.

The co-administration of Coenzyme Q10 with Clomiphene citrate has been found to be a valuable adjunct in certain patient populations. This integrated strategy aims to enhance both the quantity (through stimulation) and the quality (through cellular protection) of reproductive factors, supporting the overall goal of successful conception processes.

Regulatory References

  1. Clomiphene Citrate Definition
  2. Coenzyme Q10 Fact Sheet

What side effects are possible with Clofert MAX?

Possible Side Effects and Safety Information

The safety profile of this dual-therapy medication, which combines Clomifene and Coenzyme Q10, is primarily defined by the regulatory classifications established for the Selective Estrogen Receptor Modulator, Clomifene.

Frequency-Classified Adverse Reactions

Adverse reactions are officially categorized by their incidence according to regulatory documentation:

  • Common Reactions (may affect up to 1 in 10 users): Include vasomotor symptoms such as hot flushes, general headache, ovarian enlargement, pelvic discomfort, breast tenderness, nausea, and abnormal uterine bleeding or spotting.
  • Uncommon Reactions: Include visual disturbances (e.g., blurring, spots), depression, vertigo, nervous tension, and diarrhea.

System-Organ Classes and Serious Adverse Reactions

Side effects are grouped by the affected body system, as per official labeling. Effects are noted across the Reproductive System, Eye Disorders, Vascular Disorders, and Gastrointestinal Disorders. The regulatory framework explicitly documents risks related to two key areas:

  • Ovarian Hyperstimulation Syndrome (OHSS): This is a documented serious adverse reaction that requires immediate attention and is classified as a significant, though infrequent, risk.
  • Visual Safety: Although typically reversible, visual disturbances have been reported to become irreversible in rare, post-marketing cases, particularly when associated with increased dosage or duration of therapy.

Safety Considerations and Restrictions

Official documents define specific safety limitations and population considerations:

  • Duration-Related Risk: Regulatory data indicates an association between the development of ovarian tumors (including malignant and borderline types) and the prolonged use (one year or more) of Clomifene-containing products.
  • Contraindications: The medicine is restricted for use in the presence of pre-existing conditions such as active liver disease or dysfunction, certain types of ovarian cysts, and abnormal uterine bleeding of undetermined cause.

Overdose and Emergency Response

The official overdose profile for Clofert MAX (Clomifene component) outlines specific clinical manifestations and mandates immediate emergency actions. Documented overdose presentations include visual disturbances such as blurred vision, scotomata (visual spots or flashes), and blind spots. Additional manifestations are hot flashes, nausea, vomiting, stomach swelling, and abdominal or pelvic pain, which may signify ovarian enlargement.

Overdose risk involves potentially life-threatening outcomes, including severe complications related to Ovarian Hyperstimulation Syndrome (OHSS), thromboembolic events, and central nervous system effects.

Treatment is strictly symptomatic and supportive, as regulatory documents explicitly state that no known specific antidote exists. Officially described supportive procedures include gastric lavage, fluid and electrolyte management, and prevention of thromboembolic events.

When Urgent Medical Help Must Be Sought

Condition or Manifestation Regulator-Mandated Action
Severe Symptoms: Collapse, Seizure, or Trouble Breathing Immediately call emergency services (e.g., 911) or equivalent.
Suspected Overdose: Any other concerning sign Seek immediate medical attention or contact a Poison Control Helpline.

This structured information defines the mandatory help-seeking conditions based on the severity of the symptoms described in the official labeling.

Therapeutic Uses of Clofert MAX

What Clofert MAX Treats: Main Uses and Benefits

Clofert MAX is a medication generally used as a fertility support agent to help manage conditions that contribute to difficulty in achieving pregnancy in both women and men. It supports key reproductive functions to assist couples in their family planning.

As the main active component in Clofert MAX, Clomiphene is used to help manage symptoms associated with difficulty in becoming pregnant due to issues like absent or irregular ovulation in women, and certain challenges related to male reproductive parameters.


Primary Therapeutic Benefits

The medication is commonly used when symptoms are related to systemic imbalance affecting the reproductive system. It is applied across domains where additional symptomatic support for ovulatory function is needed in women, and is relevant for addressing symptom clusters related to low sperm count and reduced sperm activity (motility) in men. This use is common in conditions characterized by periods of heightened symptoms of reproductive difficulty, providing supportive relief when the condition involves temporary physiological imbalance.

“The medicine helps ease the overall symptom burden associated with hormonal fluctuations.”

Quick Fact: Relief for Reproductive Dysfunction This medication is relevant for easing symptoms that interfere with daily functioning related to fertility goals for both partners, providing supportive relief during episodes where symptoms lead to temporary functional strain, assisting with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The use of Clofert MAX is strictly defined by regulatory guidelines for its main active ingredient, determining eligibility based on patient health status and demographics. The medication is indicated only for use in adults of reproductive age who are seeking support for ovulatory dysfunction or certain male reproductive challenges.

Contraindicated Populations

Official labeling prohibits use for several patient groups due to regulatory non-eligibility:

  • Patients with known or suspected pregnancy (categorized as Pregnancy Category X).
  • Patients with liver disease or a history of liver dysfunction.
  • Patients with abnormal uterine bleeding of undetermined origin.
  • Patients with ovarian cysts or enlargement not attributed to Polycystic Ovary Syndrome (PCOS).
  • Patients with uncontrolled thyroid or adrenal dysfunction or an organic intracranial lesion (e.g., pituitary tumor).

Eligibility Constraints

  • Age-Related Rules: Safety and effectiveness are not established in the pediatric population (under 18 years old). The medication is not typically used in older adults.
  • Conditional Use: Use requires caution in patients with Uterine Fibroids and is not recommended for long-term cyclic therapy exceeding six total cycles. If specific visual disturbances occur during treatment, the medication must be discontinued and an evaluation performed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Clofert MAX is primarily guided by the official regulatory information for its active component, Clomiphene Citrate. The constraints on co-administration involve both specific medicines and broad categories.

Official Interaction Structure

Interaction Domain Interacting Categories/Products Regulatory Note (Constraint/Requirement)
Ovulation-Inducing Agents Other Ovulation-Inducing Drugs (e.g., Gonadotropins) Co-administration is generally not recommended as a universally accepted standard regimen is not established in official documents.
Anticoagulants Warfarin Concomitant use with Warfarin requires close monitoring of anticoagulation status (e.g., INR) due to a potential for altered anticoagulant effects.
Other Hormonal Agents Danazol, Ospemifene Use with Danazol and Ospemifene is noted for potential clinical significance, with Ospemifene combination being contraindicated in some official documents due to pharmacodynamic synergy.

Official Interaction Statements

  • The use of this product in combination with other ovulation-inducing drugs is not based on a universally accepted standard regimen, leading to restrictions on co-administration in regulatory documentation.
  • Co-administration with oral anticoagulants requires careful and frequent monitoring to ensure the anticoagulant effect remains within the desired range.
  • Official regulatory materials identify specific hormonal agents and drugs (e.g., Ospemifene) that should not be combined with this product.

Connection to the Overall Interaction Profile

The documented interaction profile is characterized by a high-level restriction against unstandardized regimens with other ovulation-inducing medicines, and specific constraints against certain anticoagulants and hormonal agents due to the risk of altered drug effects. While many interaction details are not explicitly linked to specific hepatic enzyme or transporter mechanisms in the primary official labels, the required monitoring and use restrictions define the clinical interaction structure.

Mechanism of Action

The mechanism of action for Clofert MAX is primarily driven by its active component, Clomiphene, a selective estrogen receptor modulator (SERM). Clomiphene functions as a competitive antagonist by binding to estrogen receptors, predominantly within the hypothalamus. This interaction prevents the binding of endogenous estradiol to these receptors.

The central consequence is the interruption of the hypothalamic-pituitary-ovarian axis's negative feedback loop. The hypothalamus interprets the high occupancy of its estrogen receptors by Clomiphene as a state of low circulating estrogen, despite actual levels. This systemic misinterpretation leads to a compensatory increase in the pulsatile secretion of Gonadotropin-releasing Hormone (GnRH).

The resultant elevated GnRH output stimulates the anterior pituitary gland, causing a downstream cascade that increases the release of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). This augmented gonadotropin signaling acts directly on the ovaries, promoting follicular recruitment, growth, and maturation. The increased hormonal milieu facilitates the development of a preovulatory follicle and subsequent ovulatory events.

Clofert MAX also contains Ubidecarenone, which acts as an intracellular antioxidant and coenzyme, primarily supporting cellular energy production pathways.

Dosage and Administration Information

The use of Clofert MAX (which contains the prescription component Clomifene) is governed by a strict, cyclical protocol detailed in official prescribing information. The medication is an oral tablet and is administered by mouth as the sole approved route.

Official Dosing and Administration Protocol

Usage Constraint Instruction
Route of Administration Oral.
Standard Initial Dose 50 mg (of the Clomifene component) once daily for five consecutive days.
Dose Escalation The dose is increased to 100 mg once daily for five days only if the patient did not achieve a response to the initial 50 mg course. Increasing the dose is not recommended once a response is established at 50 mg.
Timing and Frequency The 5-day course is typically started on or about the fifth day of the menstrual cycle. Doses must be taken at the same time each day for consistency.
Maximum Duration Long-term use is not recommended; treatment is generally limited to a maximum of about six total courses.
Special Conditions Patients with conditions such as Polycystic Ovary Syndrome (PCOS) are often advised to start with the lowest dose (50 mg) and shortest duration due to increased sensitivity. Use is only recommended for patients with normal liver function.

Between each 5-day course of therapy, a mandatory break is required, and precautions must be taken to exclude the presence of pregnancy before a new course is started. The cyclic nature of the administration is fundamental to the treatment protocol, defining the pattern of use as outlined by medical authorities.

Recent Clinical Evidence

Research evidence / Overview of Studies for Clofert MAX

Evidence for Female Reproductive Support (Ovulation Induction)

Research has primarily evaluated the use of the two components of Clofert MAX in short-term Randomized Controlled Trials (RCTs). These studies included infertile women of reproductive age diagnosed with Polycystic Ovary Syndrome (PCOS) who had previously demonstrated resistance to Clomiphene Citrate monotherapy. A key focus of this research has been this specific subgroup.

Studies monitored several important outcomes, including the ovulation rate measured across defined treatment cycles and clinical pregnancy rates. Research also examined physiological changes like the development of dominant follicles in the ovaries. Studies reported patterns in measured ovulation frequency and clinical pregnancy rates over the observation period in this specific resistant population. Research findings describe group patterns but do not determine whether an individual will respond similarly, as the results apply only to the populations studied.


Evidence for Male Reproductive Support (Semen Parameters)

Long-Term Evidence and Durability of Study Outcomes

Research exploring the effects of the components of Clofert MAX has mainly focused on outcomes measured during the short treatment periods required for ovulation or sperm production cycles. This means the follow-up durations were limited in many of the core studies supporting regulatory decisions. Long-term effects are not fully established regarding the durability of the initial study outcomes once the treatment period is complete. While studies help show what has been observed so far, data are still emerging regarding the sustainability of these findings over many months or years.


Key Evidence Gaps and Areas of Research Uncertainty

Several areas in the research landscape for the components of Clofert MAX remain subject to uncertainty. The primary gap is the reliance on evidence gathered for individual components or for a very specific subgroup (CC-resistant PCOS). Limited comparative evidence is available to fully define the role of this exact dual combination against all other current standard treatments. Additionally, there is limited information for long-term outcomes such as live birth rates in consolidated reviews. The evidence quality varies across studies regarding the magnitude of change in semen parameters in some male infertility studies. Research is ongoing to better clarify the full scope and long-term consequences of the use of these components.

Key Studies & References

  1. Clomiphene Citrate (NCI Drug Dictionary)
  2. Clomiphene (MedlinePlus Drug Information)
  3. Coenzyme Q10 and male infertility: a meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Clofert MAX (FAQ)


Q: How is Clofert MAX different from standard Clomiphene Citrate?

A: Clofert MAX is a dual-therapy medication that contains the primary active ingredient, Clomifene, plus an added component, Coenzyme Q10 (Ubidecarenone). Official product information shows that standard Clomiphene Citrate is a monotherapy product containing only Clomifene. The combination is formulated to provide hormonal modulation alongside cellular energy and antioxidant support.


Q: What effect does alcohol have when someone is on Clofert MAX?

A: Regulatory guidance may advise caution or avoidance when consuming alcohol while taking medications containing Clomifene. This is generally due to the potential for interactions or the risk of increasing certain side effects. Any specific guidance regarding alcohol consumption should come from a healthcare professional.


Q: Are there any specific vitamins or supplements to avoid while using Clofert MAX?

A: Official drug labels are typically specific, listing interactions with prescription medications like anticoagulants and certain hormonal agents. The regulatory guidance does not generally list interactions with all common vitamins or supplements. Disclosure of all medications and supplements being used to a healthcare provider is generally recommended.


Q: Should Clofert MAX be taken with food or on an empty stomach?

A: The official administration protocol emphasizes consistency, requiring that the dose be taken at the same time each day during the 5-day treatment course. Unless otherwise directed by a healthcare professional, official patient information generally advises continuing one's normal diet, suggesting that taking it with or without food is not the primary factor.


Q: Is Clofert MAX generally safe for women who have PCOS?

A: Yes, official prescribing information indicates that the drug is used for adult women with ovulatory dysfunction, including those with Polycystic Ovary Syndrome (PCOS). However, regulatory documents note that patients with PCOS are often advised to begin with the lowest dose due to a potentially increased sensitivity to the medication.


Q: Can Clofert MAX be taken at any time of day?

A: According to regulatory documents, the dosage for this medication must be taken at the same time each day for consistency throughout the 5-day treatment course. Consistency in timing is the primary requirement.


Q: Do men ever take Clofert MAX, and if so, for what reason?

A: Official product information for the primary component, Clomifene, states that it is sometimes used to address certain male reproductive challenges. The primary use in men is related to conditions such as oligospermia (low sperm count).


Q: How quickly should I expect to see results from Clofert MAX?

A: The medication is administered in a specific 5-day cyclical course. According to regulatory information, ovulation typically occurs 5 to 10 days after the last day of the cycle. The subsequent monitoring process is used to assess clinical outcomes.


Q: Is it normal to feel bloating or abdominal discomfort with Clofert MAX?

A: Official product information classifies pelvic discomfort and pain as common reactions. Additionally, swelling of the stomach or abdomen has been reported as a potential side effect. Any significant or severe abdominal pain is a symptom that should be reported to a healthcare provider.


Q: Is Clofert MAX available generically, or only as a brand name?

A: While Clofert MAX is a brand name for a combination product, its main component, Clomiphene Citrate, is widely available in many markets as a generic medicine.


Q: Can Clofert MAX affect mood or cause emotional changes?

A: Yes, official safety information lists nervous tension and depression among the possible side effects. Postmarketing reports have also included broader descriptions of mood changes and anxiety.


Q: What happens if a dose of Clofert MAX is missed?

A: Regulatory patient guidelines advise taking a missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, a double dose should not be taken. A healthcare provider should be consulted for specific directions regarding any missed doses.


Q: Does taking Clofert MAX increase the chance of multiple births?

A: Yes, official warnings and precautions state that the medication increases the chance of a multiple pregnancy, such as twins or triplets. This risk is typically addressed as part of the treatment planning process.


Q: Can weight gain be a side effect of Clofert MAX?

A: Official safety data lists weight gain among the less common side effects reported during the use of the active component. Any significant or unexpected weight change is a topic for discussion with a healthcare provider.


Q: Are there any dietary restrictions recommended while using Clofert MAX?

A: Regulatory patient information generally advises continuing your normal diet while taking this medication unless your healthcare provider has given specific instructions otherwise. Food is not typically listed as a factor that interacts significantly with the medicine.


Q: Does Clofert MAX influence Luteinizing Hormone (LH) levels?

A: Yes, the mechanism of action is designed to stimulate the anterior pituitary gland, which causes a downstream cascade that increases the release of both Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). This increase is key to promoting ovulation.


Q: What are the signs that Clofert MAX is working as intended?

A: Clinical studies supporting the drug’s use focus on measuring outcomes such as a rise in the ovulation rate, successful development of dominant follicles in the ovaries, and improved clinical pregnancy rates over the observation period.


Q: Why do some people experience breast tenderness with Clofert MAX?

A: Breast tenderness is a common side effect listed in official safety information. This effect is likely linked to the drug’s estrogen-modulating activity and the resultant hormonal changes, particularly the increase in estrogen and progesterone, that occur during the reproductive cycle.


Q: Are there different strengths of Clofert MAX available?

A: The administration protocol for the active component involves a standard initial daily dose, which may be increased if a response is not achieved. Therefore, two levels of dosing are referenced in regulatory documents.


Q: What should be done if an allergic reaction is suspected with Clofert MAX?

A: Regulatory patient information advises that signs of a serious allergic reaction, such as a rash, hives, or swelling of the face, lips, tongue, or throat, require immediate medical attention.


Q: Can Clofert MAX cause insomnia or changes in sleep patterns?

A: Yes, insomnia (sleeplessness) has been listed in official safety documents among the less common side effects or postmarketing reports. Persistent sleep changes are symptoms that should be discussed with a healthcare provider.


Q: How long does Clofert MAX stay in the system after the last dose?

A: Pharmacokinetic studies for the main component, Clomifene, report that it has a half-life of 4 to 7 days. Traces of the active ingredient may be detectable in the system, specifically in feces, for up to 6 weeks following the administration.


Q: Are there foods that enhance or reduce the effectiveness of Clofert MAX?

A: Official regulatory patient information generally advises continuing one's normal diet unless specifically instructed otherwise. Food is not listed as having a significant interaction that alters the medication's effectiveness.


Q: How does Clofert MAX interact with birth control pills (if taken accidentally)?

A: The drug is contraindicated for use when pregnancy is known or suspected. Combining it with other hormonal agents can have clinically significant effects. Immediate communication with a healthcare provider is necessary if a patient is taking or has accidentally taken oral contraceptives while on this medication.


Q: Can Clofert MAX affect cholesterol levels?

A: Yes, official safety documentation mentions that cases of hypertriglyceridemia (high triglycerides, a type of lipid) have been reported. The drug is also noted to potentially interfere with cholesterol synthesis pathways.


Q: Does Clofert MAX impact the quality of eggs?

A: The formulation is designed as an integrated strategy. While Clomifene promotes stimulation, the Coenzyme Q10 component is specifically included to provide robust cellular energy and antioxidant protection to reproductive tissues, which supports the overall goal of successful conception processes.


Q: Can Clofert MAX be taken alongside thyroid medication?

A: Official prescribing information states that the drug is contraindicated for patients with uncontrolled thyroid or adrenal dysfunction. It can generally be used by patients whose underlying thyroid condition is properly managed and controlled.

How should Clofert MAX be stored and disposed of?

How to Store and Dispose of Clofert MAX

Clofert MAX tablets must be stored according to official regulatory guidelines to maintain potency and safety.

Storage Requirements

The medicine requires storage at controlled room temperature, specifically maintained between 15 C and 30 C (59 F and 86 F). The product must be protected from excessive heat and moisture, and should not be frozen.

Tablets should remain in their original container and be kept tightly closed.

For safety, the medication must be stored out of the reach of children and pets in a secure location.

Disposal Instructions

Unused or expired Clofert MAX must be disposed of according to local regulations. To prevent environmental release, the product should not be disposed of via household drains or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clofert MAX found in:

A-Z Index: